DDInter1140 DDInter1676
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Mefloquine {u} (Compound) binds {v} (Gene) ACHE
Mefloquine {u} (Compound) upregulates {v} (Gene) DDIT4
Mefloquine {u} (Compound) downregulates {v} (Gene) RRP12
Mefloquine {u} (Compound) causes {v} (Side Effect) Leukocytosis
Mefloquine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metoclopramide
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Valproic acid
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Ibutilide
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Pimozide
Mefloquine (Compound) resembles Flecainide (Compound)
Mefloquine (Compound) binds ACHE (Gene)
Mefloquine (Compound) upregulates DDIT4 (Gene)
Mefloquine (Compound) downregulates RRP12 (Gene)
Mefloquine (Compound) causes Leukocytosis (Side Effect)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metoclopramide
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid
Mefloquine may lead to a major life threatening interaction when taken with Ibutilide
Mefloquine may lead to a major life threatening interaction when taken with Pimozide